Feasibility and Safety of Percutaneous Lead Revision for Subacute and Delayed Cardiac Device Lead Perforation.

Abstract

This study assessed the management approach and outcome of subacute (1 to 30days post-implantation) and delayed (>30days) cardiac perforation by pacemaker or implantable cardioverter-defibrillator (ICD) leads. Implantation of pacemaker and ICD leads is associated with a small but serious risk of cardiac perforation. Appropriate management remains uncertain. The study population included all patients referred to a single institution for subacute or delayed lead perforation after pacemaker or ICD implantation (identified after hospital discharge) during the period from 2007 to 2020. The approach and outcome of lead management were retrospectively assessed. Fifty-four cases of cardiac perforation were identified (35 females; mean age: 75.5 ± 9.7 years). Cardiac perforation was related to a pacemaker lead in 36 patients, and the perforating leads were originally placed in the right ventricular apex in 41 patients. The average time from lead implantation to first presentation of symptoms of perforation was 60.8 ± 89.1days (range 2 to 412days). Symptoms suggestive of cardiac perforation were reported by 31 patients (57.4%). Twenty three patients were asymptomatic, in whom lead perforation was discovered incidentally on radiographic imaging, suggesting lead migration or anomalous electrical data on device interrogation. In all patients, the leads were removed or repositioned by the percutaneous approach, with no major periprocedural complications and without surgical intervention. In this largest series to date of subacute or delayed cardiac device lead perforation, percutaneous repositioning or replacement of the perforating lead was found to be a safe and effective management approach.